- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06614764
Effect of Andiroba on Control of Post-whitening Tooth Sensitivity
Effect of Andiroba on Control of Post-whitening Tooth Sensitivity: a Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All groups will undergo in-office whitening treatment, carried out in 3 sessions with a 7-day interval, according to the steps described below:
Prophylaxis; Application of gingival barrier; Application of desensitizing agent or placebo, according to the established groups; Handling of the whitening material following the manufacturer's instructions: application of Whiteness HP 35% whitening gel for 15 minutes each, totaling 45 minutes; Final removal of the whitening gel and gingival barrier, followed by rinsing with water.
The application of the desensitizing agent or its placebo will follow this sequence:
Relative isolation with cotton rolls; Active application of the product on the buccal surfaces of all teeth using a rubber cup for 10 minutes; Rinsing with water.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pará
-
Belém, Pará, Brazil, 66075-110
- UFPA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- good oral hygiene
- absence of active caries lesions
- never having undergone previous whitening therapy
- not present dental hypersensitivity
- don't be a smoker
- not be pregnant
- present at least 28 teeth in the oral cavity.
Exclusion Criteria:
- volunteers who were under orthodontic treatment,
- presence of periodontal disease
- dental cracks or fractures
- restorations and prostheses on anterior teeth
- extensive molar restorations
- gastroesophageal disorders
- severe internal dental darkening
- presence of dentinal exposure in anterior and / or posterior teeth.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: PG- Placebo gel
The PG group received the application of placebo gel for post tooth bleaching sensitivity.
|
Prior to bleaching treatment with 35% hydrogen peroxide, the PG group received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
|
|
Active Comparator: GKF2- Potassium nitrate
The KF2 group received the application of potassium nitrate for post tooth bleaching sensitivity.
|
Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the KF2G received application of the potassium nitrate gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
|
|
Experimental: AG- Andiroba Gel
The AG group received the application of experimental gel of andiroba (Carapa guianensis) for post tooth bleaching sensitivity.
|
Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the AG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-whitening sensitivity assessment
Time Frame: Period: 21 days
|
To assess post-operative sensitivity, patients will be instructed to fill out a form to record daily tooth sensitivity during the 21 days of treatment, based on their individual perception of pain.
This form will be handed out at each whitening session and returned to the researcher at the following session, that is, always one week after each whitening session.
The assessment form will consist of a visual analogue scale (VAS).
This scale consists of a 10 cm horizontal line with scores of 0 and 10 at its ends, where 0 means no sensitivity and 10 means severe tooth sensitivity.
The patient will be instructed to draw a vertical line along the horizontal line of the scale, recording the intensity of tooth sensitivity per day.
So that the distance in millimeters from the zero end can later be measured with the aid of a millimeter ruler, thus obtaining the patient's pain intensity level.
|
Period: 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Color evaluation
Time Frame: Baseline (Ti) and one week after the 3rd whitening session (Tf).
|
The VITA Easyshade spectrophotometer (VITA Zahnfabrik, Bad Säckingen, Germany) will be used to measure the color, where the area of dental correspondence to be evaluated will be the middle third of the vestibular surface of the upper canines.
To standardize the color readings, silicone matrices will be made, where the impression will be extended from canine to canine.
A window will be created on the vestibular surface of each canine of the silicone guide using a metal device with a radius of 6 mm, corresponding to the diameter of the spectrophotometer tip.
Thus, the tip of the device will be inserted into the silicone guide to obtain the color parameters.
Subsequently, the color difference between the baseline (T0) and one week after the 3rd bleaching session (T1) will be calculated using the CIEDE2000 formulas (ΔE00).
|
Baseline (Ti) and one week after the 3rd whitening session (Tf).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cecy M Silva, Doctor, Universidade Federal do Para
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 81021724.2.0000.0018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg PainUnited States
-
Qi's ClinicNot yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on PG (Placebo Gel)
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Not yet recruiting
-
Prime Gene Therapeutics Co., Ltd.RecruitingLichen Simplex ChronicusChina
-
Procter and GambleCompletedOsteoarthritis, KneeHungary, United Kingdom
-
Prime Gene Therapeutics Co., Ltd.Recruiting
-
Procter and GambleCompletedMyocardial Infarction | Heart Failure | Heart EnlargementUnited States, Canada, Poland
-
Procter and GambleCompleted
-
ProGen. Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus (T2DM)Australia
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted
-
RANI TherapeuticsRecruiting
-
ProGen. Co., Ltd.Completed